While CD8+/CD3+/CD45RO+ TILs seem to be pivotal for the establishment of a TNM-I for NSCLC SCC patients, CD66b+ TANs may prove an appropriate choice for ADC patients. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.